TAO Synergies (TAOX) Total Liabilities (2019 - 2026)
TAO Synergies' (TAOX) quarterly Total Liabilities came in at $3.8 million in Q2 2026, up 108.49% on a YoY basis from $1.8 million in Q2 2025, and down 21.98% quarter-over-quarter from $4.9 million in Q1 2026.
Analysis
TAO Synergies (TAOX) Total Liabilities (2019 - 2026) Analysis & Trends
TAO Synergies (TAOX) has reported Total Liabilities for 8 consecutive years, with $3.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Total Liabilities rose 108.49% year-over-year to $3.8 million; the trailing twelve-month figure through Jun 2026 stood at $3.8 million (up 108.49% YoY), and the FY2025 full-year result was $3.9 million, down 64.07% from the prior year.
- Total Liabilities fell to $3.8 million in Q2 2026 per TAOX's latest filing, from $4.9 million in the prior quarter.
- Across five years, Total Liabilities topped out at $11.0 million in Q4 2024 and bottomed at $625979.0 in Q2 2022.
- Historically, Total Liabilities has averaged $4.7 million across 5 years, with a median of $3.9 million in 2023.
- The sharpest annual moves came in 2023 and 2025: Total Liabilities soared 943.11% in 2023, then plunged 82.59% in 2025.
- Over 5 years, Total Liabilities stood at $3.2 million in 2022, then surged by 73.17% to $5.5 million in 2023, then soared by 98.16% to $11.0 million in 2024, then plunged by 64.07% to $3.9 million in 2025, then dropped by 3.23% to $3.8 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $3.8 million, $4.9 million, and $3.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.51 Bn | 197.52 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 181.48 Bn | 178.30 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 132.45 Bn | 124.60 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 82.87 Bn | 74.88 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.72 Bn | 49.59 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 34.13 Bn | 30.82 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.29 Bn | 30.01 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 30.31 Bn | 30.31 Bn | 1.16 Mn | 384.62 Mn |
| 10 | TAO Synergies | 30.90 Mn | 30.90 Mn | - | 3.81 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.81 Mn |
| Mar 31, 2026 | 4.88 Mn |
| Dec 31, 2025 | 3.94 Mn |
| Sep 30, 2025 | 1.69 Mn |
| Jun 30, 2025 | 1.83 Mn |
| Mar 31, 2025 | 8.88 Mn |
| Dec 31, 2024 | 10.96 Mn |
| Sep 30, 2024 | 9.71 Mn |
| Jun 30, 2024 | 9.59 Mn |
| Mar 31, 2024 | 6.52 Mn |
| Dec 31, 2023 | 5.53 Mn |
| Sep 30, 2023 | 3.93 Mn |
| Jun 30, 2023 | 6.53 Mn |
| Mar 31, 2023 | 2.34 Mn |
| Dec 31, 2022 | 3.19 Mn |
| Sep 30, 2022 | 683,595.00 |
| Jun 30, 2022 | 625,979.00 |
| Mar 31, 2022 | 669,338.00 |
| Dec 31, 2021 | 1.99 Mn |
| Sep 30, 2021 | 1.01 Mn |